283 related articles for article (PubMed ID: 32043503)
1. Ellagic acid rescues motor and cognitive deficits in the R6/2 mouse model of Huntington's disease by lowering mutant huntingtin protein.
Sun X; Zhu J; Sun XY; Ji M; Yu XL; Liu RT
Food Funct; 2020 Feb; 11(2):1334-1348. PubMed ID: 32043503
[TBL] [Abstract][Full Text] [Related]
2. Intravenous immunoglobulin ameliorates motor and cognitive deficits and neuropathology in R6/2 mouse model of Huntington's disease by decreasing mutant huntingtin protein level and normalizing NF-κB signaling pathway.
Liu SY; Yu XL; Zhu J; Liu XM; Zhang Y; Dong QX; Ma S; Liu RT
Brain Res; 2018 Oct; 1697():21-33. PubMed ID: 29902468
[TBL] [Abstract][Full Text] [Related]
3. A selective inhibitor of the NLRP3 inflammasome as a potential therapeutic approach for neuroprotection in a transgenic mouse model of Huntington's disease.
Chen KP; Hua KF; Tsai FT; Lin TY; Cheng CY; Yang DI; Hsu HT; Ju TC
J Neuroinflammation; 2022 Feb; 19(1):56. PubMed ID: 35219323
[TBL] [Abstract][Full Text] [Related]
4. Small molecule modulator of protein disulfide isomerase attenuates mutant huntingtin toxicity and inhibits endoplasmic reticulum stress in a mouse model of Huntington's disease.
Zhou X; Li G; Kaplan A; Gaschler MM; Zhang X; Hou Z; Jiang M; Zott R; Cremers S; Stockwell BR; Duan W
Hum Mol Genet; 2018 May; 27(9):1545-1555. PubMed ID: 29462355
[TBL] [Abstract][Full Text] [Related]
5. Activation of NPY-Y2 receptors ameliorates disease pathology in the R6/2 mouse and PC12 cell models of Huntington's disease.
Fatoba O; Kloster E; Reick C; Saft C; Gold R; Epplen JT; Arning L; Ellrichmann G
Exp Neurol; 2018 Apr; 302():112-128. PubMed ID: 29309751
[TBL] [Abstract][Full Text] [Related]
6. Pramipexole reduces soluble mutant huntingtin and protects striatal neurons through dopamine D3 receptors in a genetic model of Huntington's disease.
Luis-Ravelo D; Estévez-Silva H; Barroso-Chinea P; Afonso-Oramas D; Salas-Hernández J; Rodríguez-Núñez J; Acevedo-Arozena A; Marcellino D; González-Hernández T
Exp Neurol; 2018 Jan; 299(Pt A):137-147. PubMed ID: 29056363
[TBL] [Abstract][Full Text] [Related]
7. Astrocyte transduction is required for rescue of behavioral phenotypes in the YAC128 mouse model with AAV-RNAi mediated HTT lowering therapeutics.
Stanek LM; Bu J; Shihabuddin LS
Neurobiol Dis; 2019 Sep; 129():29-37. PubMed ID: 31042572
[TBL] [Abstract][Full Text] [Related]
8. Normalizing glucocorticoid levels attenuates metabolic and neuropathological symptoms in the R6/2 mouse model of huntington's disease.
Dufour BD; McBride JL
Neurobiol Dis; 2019 Jan; 121():214-229. PubMed ID: 30292559
[TBL] [Abstract][Full Text] [Related]
9. Targeting CAG repeat RNAs reduces Huntington's disease phenotype independently of huntingtin levels.
Rué L; Bañez-Coronel M; Creus-Muncunill J; Giralt A; Alcalá-Vida R; Mentxaka G; Kagerbauer B; Zomeño-Abellán MT; Aranda Z; Venturi V; Pérez-Navarro E; Estivill X; Martí E
J Clin Invest; 2016 Nov; 126(11):4319-4330. PubMed ID: 27721240
[TBL] [Abstract][Full Text] [Related]
10. N-Acetylcysteine improves mitochondrial function and ameliorates behavioral deficits in the R6/1 mouse model of Huntington's disease.
Wright DJ; Renoir T; Smith ZM; Frazier AE; Francis PS; Thorburn DR; McGee SL; Hannan AJ; Gray LJ
Transl Psychiatry; 2015 Jan; 5(1):e492. PubMed ID: 25562842
[TBL] [Abstract][Full Text] [Related]
11. AMPK-α1 functions downstream of oxidative stress to mediate neuronal atrophy in Huntington's disease.
Ju TC; Chen HM; Chen YC; Chang CP; Chang C; Chern Y
Biochim Biophys Acta; 2014 Sep; 1842(9):1668-80. PubMed ID: 24946181
[TBL] [Abstract][Full Text] [Related]
12. Cerebrospinal fluid mutant huntingtin is a biomarker for huntingtin lowering in the striatum of Huntington disease mice.
Caron NS; Banos R; Aly AE; Xie Y; Ko S; Potluri N; Anderson C; Black HF; Anderson LM; Gordon B; Southwell AL; Hayden MR
Neurobiol Dis; 2022 May; 166():105652. PubMed ID: 35143966
[TBL] [Abstract][Full Text] [Related]
13. Exposure of R6/2 mice in an enriched environment augments P42 therapy efficacy on Huntington's disease progression.
Couly S; Carles A; Denus M; Benigno-Anton L; Maschat F; Maurice T
Neuropharmacology; 2021 Mar; 186():108467. PubMed ID: 33516737
[TBL] [Abstract][Full Text] [Related]
14. Development of a ligand for in vivo imaging of mutant huntingtin in Huntington's disease.
Bertoglio D; Bard J; Hessmann M; Liu L; Gärtner A; De Lombaerde S; Huscher B; Zajicek F; Miranda A; Peters F; Herrmann F; Schaertl S; Vasilkovska T; Brown CJ; Johnson PD; Prime ME; Mills MR; Van der Linden A; Mrzljak L; Khetarpal V; Wang Y; Marchionini DM; Skinbjerg M; Verhaeghe J; Dominguez C; Staelens S; Munoz-Sanjuan I
Sci Transl Med; 2022 Feb; 14(630):eabm3682. PubMed ID: 35108063
[TBL] [Abstract][Full Text] [Related]
15. A selective inhibitor of histone deacetylase 3 prevents cognitive deficits and suppresses striatal CAG repeat expansions in Huntington's disease mice.
Suelves N; Kirkham-McCarthy L; Lahue RS; Ginés S
Sci Rep; 2017 Jul; 7(1):6082. PubMed ID: 28729730
[TBL] [Abstract][Full Text] [Related]
16. Ubiquilin-1 overexpression increases the lifespan and delays accumulation of Huntingtin aggregates in the R6/2 mouse model of Huntington's disease.
Safren N; El Ayadi A; Chang L; Terrillion CE; Gould TD; Boehning DF; Monteiro MJ
PLoS One; 2014; 9(1):e87513. PubMed ID: 24475300
[TBL] [Abstract][Full Text] [Related]
17. Lycium barbarum polysaccharide attenuates the cytotoxicity of mutant huntingtin and increases the activity of AKT.
Fang F; Peng T; Yang S; Wang W; Zhang Y; Li H
Int J Dev Neurosci; 2016 Aug; 52():66-74. PubMed ID: 27196502
[TBL] [Abstract][Full Text] [Related]
18. Pharmacogenetic modulation of STEP improves motor and cognitive function in a mouse model of Huntington's disease.
García-Forn M; Martínez-Torres S; García-Díaz Barriga G; Alberch J; Milà M; Azkona G; Pérez-Navarro E
Neurobiol Dis; 2018 Dec; 120():88-97. PubMed ID: 30176350
[TBL] [Abstract][Full Text] [Related]
19. Meso scale discovery-based assays for the detection of aggregated huntingtin.
Reindl W; Baldo B; Schulz J; Janack I; Lindner I; Kleinschmidt M; Sedaghat Y; Thiede C; Tillack K; Schmidt C; Cardaun I; Schwagarus T; Herrmann F; Hotze M; Osborne GF; Herrmann S; Weiss A; Zerbinatti C; Bates GP; Bard J; Munoz-Sanjuan I; Macdonald D
PLoS One; 2019; 14(3):e0213521. PubMed ID: 30913220
[TBL] [Abstract][Full Text] [Related]
20. Correlations Between Mutant Huntingtin Aggregates and Behavioral Changes in R6/1 Mice.
Cabanas M; Piquemal M; Pistono C; Arnaud S; Rakesh D; Poinama E; Guillou JL; Garret M; Cho YH
J Huntingtons Dis; 2020; 9(1):33-45. PubMed ID: 31868674
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
